|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.12.25 - 03:54
|
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today the pricing of its previously announced underwritten public offering of 15,789,475 of its ordinary shares at a price to the public of $19.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 2,631,578 ordinary shares at an offering price of $18.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant....
|
|
|
|
|
09.12.25 - 20:42
|
What′s Going On With Wave Life Sciences Stock Tuesday? (Benzinga)
|
|
|
Wave Life Sciences rises after new WVE-007 weight-loss data and multiple analyst upgrades, alongside a $250 million offering announcement.
Latest Ratings for WVE
DateFirmActionFromTo Mar 2021SVB LeerinkReiteratesMarket Perform Dec 2020HC Wainwright & Co.AssumesBuy Oct 2020RBC CapitalInitiates Coverage OnSector Perform
View More Analyst Ratings for WVE
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
08.12.25 - 22:03
|
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health (“Wave” or “Wave Life Sciences”), announced today that it has commenced an underwritten public offering of $250 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold in the public offering on the same terms and conditions. All of the securities in the offering will be sold by Wave Life Sciences....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
